Gulf Capital completes management buyout of ECLAT Health after rapid scale-up
Abu Dhabi-headquartered private equity firm Gulf Capital has exited ECLAT Health Solutions through a management buyout that returns ownership to the company’s founders and leadership team, according to a joint statement from the investor and the business. The transaction closes a five-year partnership during which ECLAT moved from a mid-sized revenue cycle management (RCM) provider into a diversified, technology-enabled healthcare services platform serving providers and payors across the United States.
The outcome underscores two developing themes in Gulf Cooperation Council private equity: active, operationally focused ownership of overseas services platforms and flexible exit routes beyond trade sales or initial public offerings. Gulf Capital said the investment delivered a more than tenfold increase in profitability over its holding period, citing an EBITDA compound annual growth rate of about 75%.
Scale, technology and workforce expansion under PE ownership
During Gulf Capital’s ownership, ECLAT expanded its employee base from roughly 450 to over 4,000 people across the United States, India and the Philippines. The company also increased its offshore delivery footprint from two to six offices in India and the Philippines, and broadened its service mix to include risk adjustment and payer-facing solutions alongside traditional RCM services, the statement said.
A key element of the growth strategy was investment in technology. ECLAT developed a proprietary analytics and AI platform, named evaire, which the company says supports end-to-end chart retrieval and review, risk adjustment coding, confidence scoring and payer analytics. Gulf Capital and ECLAT attribute part of the operational improvement and client retention to these technology investments, alongside hiring and process upgrades.
Why a management buyout matters
Exits to management teams are not unusual, but they stand out in a market where trade buyers and IPOs remain the most visible exit mechanisms. In this case, the founders and ECLAT’s management team bought back the platform, taking control of a business they helped scale alongside Gulf Capital. The arrangement suggests several possible dynamics:
– Strategic preference and timing: Founders may prefer continued private ownership to pursue longer-term operational initiatives or selective M&A without public market pressures.
– Valuation and market conditions: Trade buyers may have been unwilling to meet Gulf Capital’s expectations or the parties concluded that an MBO better matched stakeholder objectives given prevailing market conditions.
– Continuity for clients and employees: Returning ownership to in-house leadership can provide stability for a services business with large client contracts and regulatory obligations in US healthcare.
Implications for Gulf Capital and GCC private equity
For Gulf Capital and its Fund III investors, the ECLAT transaction is presented as one of the firm’s more successful realisations. The outcome aligns with the firm’s stated Control Growth Buyout approach, which emphasizes majority stakes and active operational involvement to accelerate growth. Gulf Capital said it has deployed more than $3 billion across multiple funds and completed dozens of investments since 2006.
The deal illustrates a broader trend of GCC-based buyout firms using operational playbooks to build global service platforms, not just provide growth capital. That model can generate outsized operational improvements—but also requires deep sector knowledge, local management alignment and execution on technology and compliance in regulated markets like US healthcare.
Market context: US RCM and risk adjustment demand
The US revenue cycle management and risk adjustment market continues to attract interest from private capital due to recurring revenue models, the complexity of medical billing and rising emphasis on payer-provider data analytics. Services that combine clinical coding expertise with automation and analytics can help health systems and payors navigate regulatory scrutiny and optimize reimbursements, which supports demand for scaled, technology-enabled vendors.
However, the sector also faces regulatory sensitivities and margin pressure from client consolidation. Buyers and investors typically weigh operational scale and defensible IP, such as analytics platforms and clinical coding quality, when valuing targets. ECLAT’s reported investments in tech and payer capabilities appear designed to address those value drivers.
What to watch next
Details such as the financial terms of the buyout and any rollover or debt financing components were not disclosed. Observers will likely look for follow-up signals on ECLAT’s strategic plans under founder control, including potential tuck-in acquisitions, continued investment in AI-driven products, and expansion across payer and provider segments.
For Gulf Capital, the exit frees capital for other opportunities in its thematic sectors, including healthcare and technology. The firm’s success case at ECLAT may also reinforce the argument among limited partners for active, operationally led strategies originating in the GCC that pursue cross-border platform builds.
Bottom line: The ECLAT buyback represents a successful operational scaling story for Gulf Capital and a strategic handback to founder leadership. The path chosen – an MBO rather than a trade sale or IPO – highlights the varying exit strategies private equity sponsors are willing to deploy as they balance market conditions, portfolio objectives and management alignment.
